At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial Of The JAK-Inhibitor Ruxolitinib (INCB018424) In Combination With Exemestane For Patients With Estrogen Receptor (ER) Positive Advanced Breast Cancer)
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib and Exemestane for Estrogen-receptor Positive Invasive Metastatic Breast Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a Phase II investigator-Initiated trial of the Investigational Drug, Ruxolitinib, in combination with Exemestane in patients with estrogen-receptor positive advanced breast cancer. The objective of this study is to determine the preliminary safety and efficacy of the combination of exemestane and Ruxolitinib (INCB018424).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedMay 2012
Primary CompletionApr 2016
Study CompletionApr 2016
TodayJul 2026
First PostedMay 9, 2012
Enrollment StartApr 1, 2012
Primary CompletionApr 1, 2016
Study CompletionApr 9, 2016
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 14.1 years ago
Interventions
Ruxolitinibdrug
Exemestanedrug